Two years after a high-frequency version of Nevro’s neurostimulation system became the first spinal cord stimulator approved by the FDA with a specific indication to treat pain associated with ...
Analysis Marks the First Study of Spinal Cord Stimulation to Demonstrate Long-term, Significant, and Clinically Meaningful Reductions in HbA1c and Weight in Study Participants with Painful Diabetic ...
The company announced receiving CE Mark Certification in Europe for its HFX iQ spinal cord stimulation system. Nevro raised its 2024 adjusted EBITDA loss guidance to $18 million-$16 million from its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results